Skye Bioscience Inc.(SKYE) - 2025 Q1 - Quarterly Results

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity SAN DIEGO, CA, May 8, 2025 -- Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company"), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2025, along with key accomplishments and upcoming milestones. "In Q1, we ...